GlobeNewsWire
29 Jul 2026, 10:50 UTC · 7w ago
Verdict
Headline leans bullish. We score ETON +0.80 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Eton Pharmaceuticals has submitted a Prior Approval Supplement (PAS) to the FDA to expand the KHINDIVI label to include pediatric patients under age five.
More positive than 92% of claims this week
The company's new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, an FDA-approved hydrocortisone granule formulation.
Continue reading
5 related stories
More positive than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
The company expects a potential label expansion in the first half of 2027.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company submitted a Prior Approval Supplement to expand the label of KHINDIVI to younger pediatric patients, representing a key strategic milestone.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
3h ago
+22.4%
Price agrees with the score
$57.09 vs $46.66 close before publication (Jul 28) · not market-adjusted
ETON chart →